PTC Therapeutics (PTCT) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 98.6% versus a loss of 1.1%. Over five years, TVTX leads with a +112.4% price change compared with +66.0% for PTCT. PTC Therapeutics is the larger company by market cap ($5.22 billion vs $4.91 billion), about 1.1 times the size.
On valuation, Travere Therapeutics trades at a lower forward P/E (9.2x vs 23.4x for PTC Therapeutics). PTC Therapeutics converts more of its revenue into profit, with a net margin of 39.4% versus -5.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTCT | TVTX |
|---|---|---|
| Share price | $62.56 | $52.04 |
| Market cap | $5.22B | $4.91B |
| 1-day change | -1.06% | -2.62% |
| YTD return | -16.76% | +36.19% |
| 1-year return | -1.06% | +98.63% |
| 5-year return | +66.00% | +112.41% |
| Forward P/E | 23.37 | 9.23 |
| EPS (TTM) | $-0.65 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.73B | $490.73M |
| Revenue growth (YoY) | +114.51% | +110.45% |
| Net income (latest FY) | $682.64M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | 50.09% | -12.80% |
| Net margin | 39.44% | -5.21% |
| 52-week high | $90.87 | $68.73 |
| 52-week low | $61.23 | $22.59 |
| Distance from 52-week high | -31.15% | -24.28% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +62.71% | +44.52% |
| Average volume | 1.14M | 1.58M |
| Shares outstanding | 83.46M | 94.26M |
| Employees | 991 | 497 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TVTX has outperformed PTCT by 99.7 percentage points over the past year.
- PTC Therapeutics is more profitable, keeping 39.4 cents of every revenue dollar as net income versus -5.2 cents for Travere Therapeutics.
- The two companies sit in different sectors: PTC Therapeutics in Health Care and Travere Therapeutics in Healthcare.
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Healthcare · Biotechnology · 497 employees
PTCT vs TVTX FAQ
Which is bigger, PTC Therapeutics or Travere Therapeutics?
PTC Therapeutics (PTCT) is larger, with a market capitalization of $5.22B compared with $4.91B for Travere Therapeutics (TVTX).
Which stock has performed better over the past year, PTCT or TVTX?
TVTX returned +98.63% over the past 12 months, compared with -1.06% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are PTC Therapeutics and Travere Therapeutics in the same industry?
No. PTC Therapeutics is in the Health Care sector, while Travere Therapeutics is in Healthcare.